Niels Høiby Selected Research

Alginates

1/2018	IgG avidity to Pseudomonas aeruginosa over the course of chronic lung biofilm infection in cystic fibrosis.
4/2017	Diagnosis of biofilm infections in cystic fibrosis patients.
1/2016	OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model.
3/2013	Pseudomonas aeruginosa biofilm aggravates skin inflammatory response in BALB/c mice in a novel chronic wound model.
11/2010	Pseudomonas aeruginosa biofilms in cystic fibrosis.
6/2010	Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts.
6/2009	Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
2/2009	Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis.
10/2007	Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.
9/2005	Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Niels Høiby Research Topics

Disease

98	Infections 08/2022 - 05/2001
47	Cystic Fibrosis (Mucoviscidosis) 01/2022 - 12/2002
14	Wounds and Injuries (Trauma) 07/2022 - 05/2006
14	Persistent Infection 01/2018 - 11/2003
11	Inflammation (Inflammations) 01/2022 - 02/2009
5	Bacterial Infections (Bacterial Infection) 01/2022 - 09/2006
4	Pneumonia (Pneumonitis) 12/2020 - 06/2005
4	Burns 02/2018 - 01/2005
3	Respiratory Tract Infections (Respiratory Tract Infection) 03/2022 - 05/2006
3	Sepsis (Septicemia) 05/2019 - 05/2006
3	Lung Diseases (Lung Disease) 12/2018 - 11/2003
3	Urinary Tract Infections (Urinary Tract Infection) 04/2017 - 04/2002
3	Pseudomonas Infections 01/2016 - 04/2004
3	Foreign Bodies (Foreign Body) 03/2015 - 05/2012
2	Hypoxia (Hypoxemia) 01/2022 - 01/2014
2	Endocarditis 01/2022 - 01/2019
2	Bacteremia 11/2021 - 09/2015
2	AIDS-Related Complex (ARC) 05/2019 - 03/2016
2	Communicable Diseases (Infectious Diseases) 05/2019 - 08/2011
2	Sinusitis 04/2017 - 01/2013
2	Peritonitis 11/2009 - 11/2009
2	Body Weight (Weight, Body) 11/2009 - 08/2002
2	Cross Infection (Nosocomial Infection) 10/2008 - 09/2008
1	Latent Infection 01/2022
1	Asymptomatic Infections 01/2022
1	Cough 04/2019
1	Hypesthesia (Numbness) 04/2017

Drug/Important Bio-Agent (IBA)

56	Anti-Bacterial Agents (Antibiotics)IBA 08/2022 - 11/2003
16	AlginatesIBA 01/2018 - 08/2002
13	Immunoglobulin G (IgG)IBA 01/2022 - 05/2001
12	CytokinesIBA 01/2022 - 09/2003
11	AntibodiesIBA 01/2020 - 12/2002
9	Ciprofloxacin (Cipro)FDA LinkGeneric 07/2022 - 04/2010
7	Colistin (Coly-Mycin)FDA Link 01/2019 - 09/2008
7	Tobramycin (Nebcin)FDA LinkGeneric 01/2019 - 12/2005
6	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2017 - 06/2005
5	Secretory Immunoglobulin A (SIgA)IBA 04/2019 - 12/2012
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2017 - 06/2005
4	Oxygen (Dioxygen)IBA 01/2019 - 03/2011
3	Pharmaceutical PreparationsIBA 03/2022 - 08/2003
3	Immunoglobulin A (IgA)IBA 01/2020 - 01/2013
3	Imipenem FDA Link 01/2020 - 09/2007
3	Antigen-Antibody Complex (Immune Complex)IBA 01/2018 - 11/2010
3	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 08/2009
3	Polymyxins (Polymyxin)IBA 05/2013 - 12/2011
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 07/2010 - 09/2003
2	MacrolidesIBA 07/2022 - 04/2004
2	Interleukin-2 (IL2)IBA 01/2022 - 12/2020
2	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 04/2017
2	Peptides (Polypeptides)IBA 01/2022 - 01/2019
2	Azithromycin (Zithromax)FDA LinkGeneric 01/2021 - 01/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2018 - 07/2016
2	EnzymesIBA 01/2017 - 09/2007
2	Proteins (Proteins, Gene)FDA Link 07/2016 - 07/2010
2	AntioxidantsIBA 03/2015 - 04/2012
2	Antimicrobial PeptidesIBA 02/2014 - 11/2009
2	AgarIBA 07/2013 - 11/2010
2	SolutionsIBA 06/2013 - 04/2012
2	IronIBA 01/2011 - 07/2010
2	Ceftazidime (Fortum)FDA LinkGeneric 04/2010 - 12/2002
2	Meropenem (Merrem)FDA LinkGeneric 04/2010 - 09/2007
2	plectasinIBA 11/2009 - 11/2009
2	Virulence Factors (Pathogenicity Factors)IBA 10/2007 - 05/2007
2	beta-Lactamases (beta-Lactamase)IBA 09/2007 - 12/2002
2	SulfonamidesIBA 11/2003 - 04/2002
1	Interleukin-5 (Interleukin 5)IBA 01/2022
1	Interleukin-4 (Interleukin 4)IBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	CD40 Ligand (CD40L)IBA 01/2022
1	lactoferricin BIBA 01/2022
1	FibrinIBA 11/2021
1	IgYIBA 01/2021
1	Tigecycline (Tygacil)FDA Link 01/2020
1	Moxifloxacin (Avelox)FDA Link 01/2020
1	Kanamycin FDA Link 01/2020
1	Cefoxitin (Cefoxitin Sodium)FDA LinkGeneric 01/2020
1	Linezolid (Zyvox)FDA Link 01/2020
1	Amikacin (A.M.K)FDA LinkGeneric 01/2020
1	Sulfamethoxazole FDA LinkGeneric 01/2020
1	Rifampin (Rifampicin)FDA LinkGeneric 01/2020
1	Clarithromycin (Biaxin)FDA LinkGeneric 01/2020
1	Trimethoprim (Proloprim)FDA LinkGeneric 01/2020
1	PeptidomimeticsIBA 01/2019
1	Dabigatran FDA Link 01/2019
1	PeptoidsIBA 01/2019
1	Lysine (L-Lysine)FDA Link 01/2019
1	IntegrinsIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 08/2018
1	thiocyanateIBA 01/2018
1	Sepharose (Agarose)IBA 11/2017
1	ChemokinesIBA 01/2017
1	SteroidsIBA 01/2017
1	ImmunosorbentsIBA 01/2017

Therapy/Procedure

18	Therapeutics 03/2022 - 12/2002
4	Lung Transplantation 01/2020 - 10/2005
3	Catheters 04/2017 - 10/2008
1	Critical Care (Surgical Intensive Care) 01/2022
1	Hyperbaric Oxygenation 01/2022
1	Immunomodulation 01/2021
1	Phage Therapy 01/2019